Attached files
| file | filename |
|---|---|
| 10-K - 10-K - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231x10k.htm |
| EX-32.1 - EX-32.1 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex321e5688d.htm |
| EX-31.1 - EX-31.1 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex311f8c49a.htm |
| EX-21.1 - EX-21.1 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex21121ead2.htm |
| EX-10.40 - EX-10.40 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex1040bc0cf.htm |
| EX-4.5 - EX-4.5 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex4549cc3b5.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
NeuroBo Pharmaceuticals, Inc.
Boston, MA
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-252412, No. 333-220315 and 333-217296) and Form S-8 (No, 333-237535, No. 333-232667, 333-225435, 333-222675, 333-213946 and 333-213014) of NeuroBo Pharmaceuticals, Inc. (the “Company”) of our report dated April 15, 2021, relating to the consolidated financial statements which appears in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Boston, Massachusetts
April 15, 2021